Current Osteoporosis Reports

, Volume 10, Issue 4, pp 303–311 | Cite as

Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults

Epidemiology and Pathophysiology (RA Adler, Section Editor)

Abstract

Psychotropic drugs are a crucial element of treatment for psychiatric disorders; however there is an established association between many classes of psychotropic medications and fracture risk among older adults, and growing evidence that some classes of medications may also impact bone mineral density (BMD). In this paper we review recent epidemiologic research on the association between psychotropic medications and osteoporosis, and discuss current controversies and unresolved issues surrounding this relationship. Key areas in need of focused inquiry include resolving whether the apparent association between psychotropic medications and BMD is due to confounding by indication, whether this relationship differs for men and women, and whether the implications of these medications for bone health vary over the life course. Clinical research to delineate the risk/benefit ratio of psychotropic medications for older adults, particularly those who are at high risk for fracture, is also needed to facilitate prescribing decisions between patients and physicians.

Keywords

Epidemiology Aging Psychiatry Polypharmacy Medications Osteoporosis 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    National Osteoporosis Foundation. [Online]. Available at: http://www.nof.org/node/40. Accessed August 14, 2012.
  2. 2.
    Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–75.PubMedCrossRefGoogle Scholar
  3. 3.
    US Department of Health and Human Services. Mental Health: a report of the Surgeon General. 1999.Google Scholar
  4. 4.
    Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Zuvekas SH. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff (Millwood). 2005;24:195–205.CrossRefGoogle Scholar
  6. 6.
    Paulose-Ram R, Safran MA, Jonas BS, et al. Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf. 2007;16:560–70.PubMedCrossRefGoogle Scholar
  7. 7.
    National Institute for Health Care Management Research and Educational Foundation. Prescription Drug Expenditures in 2001: another year of escalating costs [Online]. Available at: http://www.nihcm.org/pdf/spending2001.pdf. Accessed August 14, 2012.
  8. 8.
    Middleton N, Gunnell D, Whitley E, et al. Secular trends in antidepressant prescribing in the UK, 1975–1998. J Public Health Med. 2001;23:262–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review [internet]. Rockville: Agency for Healthcare Research and Quality; 2011.Google Scholar
  10. 10.
    •• Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51:606–13. Comprehensive review of the biological mechanisms linking SSRIs and bone mineral density.PubMedCrossRefGoogle Scholar
  11. 11.
    •• Oderda LH, Young JR, Asche CV, et al. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother. 2012;46:917–28. Recent meta-analysis of the association between first-generation and second-generation antidepressant and antipsychotic drugs.PubMedCrossRefGoogle Scholar
  12. 12.
    Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30:171–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17:807–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women’s health initiative (WHI). J Bone Miner Res. 2010;25:873–81.PubMedGoogle Scholar
  16. 16.
    Cetinkaya Y, Kurtulmus YS, Tutkavul K, et al. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand. 2009;120:170–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8:34–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Svalheim S, Roste LS, Nakken KO, et al. Bone health in adults with epilepsy. Acta Neurol Scand Suppl. 2011;(191):89–95.Google Scholar
  19. 19.
    Triantafyllou N, Lambrinoudaki I, Armeni E, et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci. 2010;290:131–4.PubMedCrossRefGoogle Scholar
  20. 20.
    • Graham SM, Howgate D, Anderson W, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10:575–602. Comprehensive review of the association between antipsychotics and bone mineralization and fracture incidence.PubMedCrossRefGoogle Scholar
  21. 21.
    Renn JH, Yang NP, Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord. 2010;11:35.PubMedCrossRefGoogle Scholar
  22. 22.
    • Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56–60. Reports on the relationship between psychotropic medications, psychiatric disease, and osteoporosis in postmenopausal women.PubMedCrossRefGoogle Scholar
  23. 23.
    Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28:384–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Mezuk B, Morden NE, Ganoczy D, et al. Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatr. 2010;18:245–55.CrossRefGoogle Scholar
  25. 25.
    Mezuk B. Affective disorders, bone metabolism, and osteoporosis. 2008;6:101–102–13.Google Scholar
  26. 26.
    Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008;23:567–74.PubMedCrossRefGoogle Scholar
  27. 27.
    Mezuk B, Eaton WW, Golden SH, et al. Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci. 2008;63:1410–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010;46:13–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28:411–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003;158:77–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–94.PubMedCrossRefGoogle Scholar
  32. 32.
    Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf. 2011;10:265–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies. Osteoporos Int. 2012;23:365–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Ashjazadeh N, Zamani A, Pourjafar M, et al. Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy. Arch Iran Med. 2009;12:550–4.PubMedGoogle Scholar
  35. 35.
    Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Kunimatsu T, Kimura J, Funabashi H, et al. The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol. 2010;58:360–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Pack AM. Genetic variation may clarify the relationship between epilepsy, antiepileptic drugs, and bone health. Eur J Neurol. 2011;18:3–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477–86.PubMedCrossRefGoogle Scholar
  39. 39.
    Calarge CA, Zimmerman B, Xie D, et al. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71:338–47.PubMedCrossRefGoogle Scholar
  40. 40.
    Calarge CA, Ellingrod VL, Zimmerman B, et al. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011;72:1685–90.PubMedCrossRefGoogle Scholar
  41. 41.
    Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008;8:133–45.PubMedGoogle Scholar
  42. 42.
    Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146:685–93.PubMedCrossRefGoogle Scholar
  43. 43.
    Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19:1420–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Bliziotes M, Eshleman A, Burt-Pichat B, et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone. 2006;39:1313–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int. 2011;88:476–84.PubMedCrossRefGoogle Scholar
  46. 46.
    Chau K, Atkinson SA, Taylor VH. Are selective serotonin reuptake inhibitors a secondary cause of low bone density? J Osteoporos. 2012;2012:323061.PubMedGoogle Scholar
  47. 47.
    Pack AM, Reddy DS, Duncan S, et al. Neuroendocrinological aspects of epilepsy: important issues and trends in future research. Epilepsy Behav. 2011;22:94–102.PubMedCrossRefGoogle Scholar
  48. 48.
    Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol. 2008;83:305–28.PubMedCrossRefGoogle Scholar
  49. 49.
    Verrotti A, Coppola G, Parisi P, et al. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112:1–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Beerhorst K, Schouwenaars FM, Tan IY, et al. Epilepsy: fractures and the role of cumulative antiepileptic drug load. Acta Neurol Scand. 2012;125:54–9.PubMedCrossRefGoogle Scholar
  51. 51.
    El-Hajj Fuleihan G, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone. 2008;43:149–55.PubMedCrossRefGoogle Scholar
  52. 52.
    Lado F, Spiegel R, Masur JH, et al. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epilepsy Res. 2008;78:155–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;71 Suppl 2:S42–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia. 2011;52:1884–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;284:749–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28 Suppl 2:55–68.PubMedCrossRefGoogle Scholar
  57. 57.
    Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28 Suppl 2:109–23.PubMedCrossRefGoogle Scholar
  58. 58.
    Doknic M, Maric NP, Britvic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94:246–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Bataille-Simoneau N, Gerland K, Chappard D, et al. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun. 1996;229:323–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem. 2009;107:677–85.PubMedCrossRefGoogle Scholar
  61. 61.
    Klungel OH, Martens EP, Psaty BM, et al. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004;57:1223–31.PubMedCrossRefGoogle Scholar
  62. 62.
    Thomas D, Stram D, Dwyer J. Exposure measurement error: influence on exposure-disease. Relationships and methods of correction. Annu Rev Public Health. 1993;14:69–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Mojtabai R. Unmet need for treatment of major depression in the United States. Psychiatr Serv. 2009;60:297–305.PubMedCrossRefGoogle Scholar
  64. 64.
    Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int. 2008;19:1–12.PubMedCrossRefGoogle Scholar
  65. 65.
    Bab I, Yirmiya R. Depression, selective serotonin reuptake inhibitors, and osteoporosis. Curr Osteoporos Rep. 2010;8:185–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Cizza G, Primma S, Coyle M, et al. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res. 2010;42:467–82.PubMedCrossRefGoogle Scholar
  67. 67.
    American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRefGoogle Scholar
  68. 68.
    Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods. 2010;15:234–49.PubMedCrossRefGoogle Scholar
  69. 69.
    Stuart EA, Marcus SM, Horvitz-Lennon MV, et al. Using non-experimental data to estimate treatment effects. Psychiatr Ann. 2009;39:41451.PubMedCrossRefGoogle Scholar
  70. 70.
    Wu Q, Magnus JH, Liu J, et al. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos Int. 2009;20:1309–20.PubMedCrossRefGoogle Scholar
  71. 71.
    Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24:49–54.PubMedCrossRefGoogle Scholar
  72. 72.
    Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229.PubMedCrossRefGoogle Scholar
  73. 73.
    Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–51.PubMedCrossRefGoogle Scholar
  74. 74.
    • Cizza G, Mistry S, Nguyen VT, et al. Do premenopausal women with major depression have low bone mineral density? a 36-month prospective study. PLoS One. 2012;7:e40894. Investigation of the influence of major depression on osteoporosis risk among younger women.PubMedCrossRefGoogle Scholar
  75. 75.
    Eskandari F, Martinez PE, Torvik S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007;167:2329–36.PubMedCrossRefGoogle Scholar
  76. 76.
    Battaglino R, Vokes M, Schulze-Spate U, et al. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem. 2007;100:1387–94.PubMedCrossRefGoogle Scholar
  77. 77.
    Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.PubMedCrossRefGoogle Scholar
  78. 78.
    Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010;(42):1–8.Google Scholar
  79. 79.
    Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516–23.PubMedCrossRefGoogle Scholar
  80. 80.
    Caughey GE, Roughead EE, Shakib S, et al. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing. 2010;39:488–94.PubMedCrossRefGoogle Scholar
  81. 81.
    Gosch M, Jeske M, Kammerlander C, et al. Osteoporosis and polypharmacy. Z Gerontol Geriatr. 2012.Google Scholar
  82. 82.
    Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12:425–30.PubMedCrossRefGoogle Scholar
  83. 83.
    Kao S, Wang YC, Tzeng YM, et al. Interactive effect between depression and chronic medical conditions on fall risk in community-dwelling elders. Int Psychogeriatr. 2012;24:1409–18.PubMedCrossRefGoogle Scholar
  84. 84.
    Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–95.PubMedCrossRefGoogle Scholar
  85. 85.
    Kragh A, Elmstahl S, Atroshi I. Older adults’ medication use 6 months before and after hip fracture: a population-based cohort study. J Am Geriatr Soc. 2011;59:863–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Slomski A. Falls from taking multiple medications may be a risk for both young and old. JAMA. 2012;307:1127–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Petty DR, House A, Knapp P, et al. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing. 2006;35:523–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Dickinson R, Knapp P, House AO, et al. Long-term prescribing of antidepressants in the older population: a qualitative study. Br J Gen Pract. 2010;60:e144–55.PubMedCrossRefGoogle Scholar
  89. 89.
    Lasserre A, Younes N, Blanchon T, et al. Psychotropic drug use among older people in general practice: discrepancies between opinion and practice. Br J Gen Pract. 2010;60:e156–62.PubMedCrossRefGoogle Scholar
  90. 90.
    Siriwardena AN. Why do GPs prescribe psychotropic drugs when they would rather provide alternative psychological interventions? Br J Gen Pract. 2010;60:241–2.PubMedCrossRefGoogle Scholar
  91. 91.
    Middleton H, Moncrieff J. ‘They won’t do any harm and might do some good’: time to think again on the use of antidepressants? Br J Gen Pract. 2011;61:47–9.PubMedCrossRefGoogle Scholar
  92. 92.
    •• Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. Large study of adverse clinical events due to pharmacologic treatment of depression among older adults.PubMedCrossRefGoogle Scholar
  93. 93.
    Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Epidemiology and Community HealthVirginia Commonwealth University School of MedicineRichmondUSA

Personalised recommendations